Methadone

• 

  Subject Areas on Research

  • A case of infant delirium in the neonatal intensive care unit. 
  • A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release. 
  • Alcohol consumption in persons on methadone maintenance therapy. 
  • Alcoholism among narcotic addicts and patients on methadone maintenance. 
  • Alcoholism as a risk factor in methadone maintenance. A randomized controlled trial. 
  • Alteration by methadone of catecholamine uptake and release in isolated rat adrenomedullary storage vesicles. 
  • Alterations in the development of catecholamine turnover induced by perinatal methadone: differences in central vs. peripheral sympathetic nervous systems. 
  • An intracellular opiate receptor. 
  • Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome. 
  • Assessing pathological detoxification fear among methadone maintenance patients: the DFSS. 
  • Bioavailabilities of rectal and oral methadone in healthy subjects. 
  • Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. 
  • Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. 
  • Catecholamine synthesis, storage and release in adrenal medulla and whole brain during acute and chronic methadone administration. 
  • Catecholaminergic regulation of opiate-stimulated growth hormone secretion in the developing rat. 
  • Cocaine use by clients in methadone programs: significance, scope, and behavioral interventions. 
  • Conservative Management of Neuropathic Pain in a Patient With Pancoast-Tobias Syndrome: A Case Report. 
  • Current Concepts in Methadone Metabolism and Transport. 
  • Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics. 
  • Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir. 
  • Delays in growth and biochemical development of rat brain caused by maternal methadone administration: are the alterations in synaptogenesis and cellular maturation independent of reduced maternal food intake? 
  • Development of central and peripheral catecholaminergic systems in rats addicted perinatally to methadone. 
  • Differences in Methadone Metabolism by CYP2B6 Variants. 
  • Disposition of nasal, intravenous, and oral methadone in healthy volunteers. 
  • Do methadone patients substitute other drugs for heroin? Predicting substance use at 1-year follow-up. 
  • Early outcomes following low dose naltrexone enhancement of opioid detoxification. 
  • Effect of chronic methadone administration on neuroendocrine function in developing rats. 
  • Effect of chronic methadone administration on neuroendocrine function in young adult rats. 
  • Effects of maternal methadone administration on ornithine decarboxylase in brain and heart of the offspring: relationships of enzyme activity to dose and to growth impairment in the rat. 
  • Effects of neonatal or maternal methadone administration on ornithine decarboxylase activity in brain and heart of developing rats. 
  • Effects of perinatal exposure to methadone on development of neurotransmission: biochemical bases for behavioral alterations. 
  • Emergency therapeutical approach simulating ultrarapid opioid detoxification in methadone withdrawal precipitated by erroneous administration of naltrexone. 
  • Enantiomeric metabolic interactions and stereoselective human methadone metabolism. 
  • Endocrine consequences of perinatal methadone exposure. 
  • Endocrine effects of methadone in rats; acute effects in adults. 
  • Facilitators and Barriers to Naloxone Kit Use Among Opioid-Dependent Patients Enrolled in Medication Assisted Therapy Clinics in North Carolina. 
  • Failure of mean red cell volume to serve as a biologic marker for alcoholism in narcotic dependence. A randomized control trial. 
  • Follow-up of methadone maintenance patients hospitalized for abuse of alcohol and barbiturates. 
  • Identification and treatment of alcoholics who use opiates. 
  • Implementation of a comprehensive hospitalist-led initiative to improve care for patients with opioid use disorder. 
  • Influence of HIV antiretrovirals on methadone N-demethylation and transport. 
  • Infrequent illicit methadone use among stimulant-using patients in methadone maintenance treatment programs: a national drug abuse treatment clinical trials network study. 
  • Intraoperative Methadone for the Prevention of Postoperative Pain: A Randomized, Double-blinded Clinical Trial in Cardiac Surgical Patients. 
  • Intraoperative Methadone in Same-Day Ambulatory Surgery: A Randomized, Double-Blinded, Dose-Finding Pilot Study. 
  • Intraoperative methadone: rediscovery, reappraisal, and reinvigoration? 
  • Is treatment for alcoholism effective in persons on methadone maintenance? 
  • Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). 
  • Lefetamine: new abuse of an old drug--clinical evaluation of opioid activity. 
  • Maternal methadone administration: deficit in development of alpha-noradrenergic responses in developing rat brain as assessed by norepinephrine stimulation of 33Pi incorporation into phospholipids in vivo. 
  • Maturation of sympathetic neurotransmission in the rat heart. I. Ontogeny of the synaptic vesicle uptake mechanism and correlation with development of synaptic function. Effects of neonatal methadone administration on development of synaptic vesicles. 
  • Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective? 
  • Mechanism of autoinduction of methadone N-demethylation in human hepatocytes. 
  • Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. 
  • Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. 
  • Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. 
  • Medication-Based Treatment to Address Opioid Use Disorder. 
  • Medications that prolong the QT interval. 
  • Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. 
  • Methadone Disposition: Implementing Lessons Learned. 
  • Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6. 
  • Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. 
  • Methadone and Ketamine: Boosting Benefits and Still More to Learn. 
  • Methadone and cocaine. 
  • Methadone inhibits serotonin and norephinephrine uptake into rat brain synaptosomes and synaptic vesicles in vitro but not in vivo. 
  • Methadone maintenance in pregnancy: a reappraisal. 
  • Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. 
  • Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition. 
  • Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. 
  • Morphine vs Methadone Treatment for Infants with Neonatal Abstinence Syndrome. 
  • Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes. 
  • Non-neurogenic mechanism for reserpine-induced release of catecholamines from the adrenal medulla of neonatal rats: possible modulation by opiate receptors. 
  • Norepinephrine content of the rat kidney during development: alterations induced by perinatal methadone. 
  • Ontogeny of endocrine responses to methadone in rats. 
  • Opiate addiction and alcoholism: the feasibility of combined treatment approaches. 
  • Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. 
  • Opioid Half-lives and Hemlines: The Long and Short of Fashion. 
  • Opioid Management in Pregnancy and Postpartum. 
  • Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial. 
  • Opioid use affects antioxidant activity and purine metabolism: preliminary results. 
  • Perinatal exposure to methadone: how do early biochemical alterations cause neurofunctional disturbances? 
  • Perinatal methadone addiction affects brain synaptic development of biogenic amine systems in the rat. 
  • Perioperative pharmacokinetics of methadone in adolescents. 
  • Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease. 
  • Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System. 
  • Precocious development of sympatho-adrenal function in rats whose mothers received methadone. 
  • Predicting cocaine use among methadone patients: analysis of findings from a national study. 
  • Prevalence and diagnostic reliability of methadone maintenance detoxification fear. 
  • Primary Care Providers And Specialists Deliver Comparable Buprenorphine Treatment Quality. 
  • Problem drinking and low-dose naltrexone-assisted opioid detoxification. 
  • Prolongation of QTc intervals and risk of death among patients with sickle cell disease. 
  • Psychotherapeutic treatment of opiate addiction. 
  • Quality improvement initiative to improve inpatient outcomes for Neonatal Abstinence Syndrome. 
  • Referring heroin users from compulsory detoxification centers to community methadone maintenance treatment: a comparison of three models. 
  • Reply to comment on: Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease. 
  • Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report. 
  • Responses of heart ornithine decarboxylase and adrenal catecholamines to methadone and sympathetic stimulants in developing and adults rats. 
  • Role of CYP2B6 in stereoselective human methadone metabolism. 
  • Role of cytochrome P4502B6 in methadone metabolism and clearance. 
  • Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. 
  • Serendipitous rapid detoxification from opiates: the importance of time-dependent processes. 
  • Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine. 
  • Stereoselective determination of methadone and the primary metabolite EDDP in human plasma by automated on-line extraction and liquid chromatography mass spectrometry. 
  • Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. 
  • The ability of a Self-Administered Alcohol Screening Test (mSAAST) to detect future excessive alcohol consumption in persons on methadone maintenance. 
  • The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal. 
  • The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints. 
  • The effect of alcoholism in methadone-maintained persons on productive activity: a randomized control trial. 
  • The effect of intraoperative methadone during pediatric cardiac surgery on postoperative opioid requirements. 
  • The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. 
  • The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam. 
  • Toward precision prescribing for methadone: Determinants of methadone deposition. 
  • Toxic effects of maternal methadone administration on cardiac development in the neonatal rat: potential participation of altered polyamine levels in growth impairment. 
  • Use of physiologically-based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity. 
  • Use of very low-dose naltrexone during opiate detoxification. 
  • Using a latent variable approach to inform gender and racial/ethnic differences in cocaine dependence: a National Drug Abuse Treatment Clinical Trials Network study. 
  • Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. 
• 

  Keywords of People

  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine